CVS Health (CVS) closed at $56.25 in the latest trading session, marking a -1.94% move from the prior day.
CVS Health faces outpatient and supplemental benefits pressure within Health Care Benefits.
CVS Health dropped ~10% following Q3 earnings, impacted by a $1.1B Medicare charge and a $1.2B restructuring charge. CVS's FY2024 EPS forecast is $6.47, down 26.01% YoY, reflecting financial challenges, but FY2025 recovery is projected at $7.30, up 13%. The company's revenue is estimated at $369.25 billion in 2024, with upward revisions suggesting optimism, projected to reach $386.28 billion by 2025.
Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
At the present rate, it will take 81 years to achieve gender parity among the CEO class
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
The new chief executive officer of CVS Health is schooled in many of the traditions that built the company into a major player in both health insurance and healthcare delivery. So don't look for David Joyner to move away from vertical integration as both a provider and a health insurance company.
Workers at seven CVS pharmacies in California are now on strike, seeking better pay and health care, as the stores remain open and staffed by managers and nonunion employees.
If you buy these stocks, you might be in for serious disappointment when they underperform.
CVS Health (CVS) stock tumbled about 5% in Friday after the pharmacy and healthcare giant announced the replacement of Chief Executive Officer (CEO) Karen Lynch with David Joyner, a longtime company veteran who most recently ran Caremark, its pharmacy benefit manager (PBM).
CVS (CVS) has announced that it has replaced its CEO Karen Lynch with longtime executive David Joyner, sending shares sinking in Friday's trading session. Stephanie Davis, Barclays senior research analyst and managing director, joins Market Domination to discuss the leadership shakeup and what it means for CVS moving forward.
George Hill, Deutsche Bank managing director, joins 'Closing Bell Overtime' to talk CVS' C-Suite shakeup and what it means for the company.